Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab.
The human anti-epidermal growth factor receptor (EGFR) monoclonal antibody, panitumumab, represents a significant advance in the treatment of colorectal cancer. The strategy to target this receptor is based on sound cancer biology demonstrating its essential role in colorectal carcinogenesis. Panitumumab, unlike its predecessor, cetuximab, is fully human and thus reduces the incidence of hypersensitivity reactions. But, in several clinical trials, unexpected toxicities have become more apparent, raising concerns of how readily panitumumab can succeed cetuximab. This paper reviews the development of this agent and the pivotal clinical trials that help our understanding of its optimal use in colorectal cancer treatment.
Kim
George P
GP
College of Medicine, Mayo Clinic.
Grothey
Axel
A
J Clin Oncol. 2002 Sep 15;20(18 Suppl):1S-13S
12235219
Clin Colorectal Cancer. 2007 Mar;6(6):427-32
17531105
J Clin Oncol. 2008 Apr 1;26(10):1626-34
18316791
N Engl J Med. 2004 Dec 30;351(27):2883
15625347
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
J Mammary Gland Biol Neoplasia. 1997 Apr;2(2):165-74
10882302
N Engl J Med. 2004 Jul 22;351(4):337-45
15269313
J Clin Oncol. 2004 Apr 1;22(7):1201-8
14993230
Cancer. 2007 Sep 1;110(5):980-8
17671985
J Clin Oncol. 2001 Sep 15;19(18 Suppl):41S-44S
11560970
J Clin Oncol. 2008 May 10;26(14):2311-9
18390971
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):984-90
14967460
N Engl J Med. 2007 Nov 15;357(20):2040-8
18003960
Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16
16829981
Crit Rev Oncol Hematol. 2001 Apr;38(1):17-23
11255078
Cell. 1990 Jun 1;61(5):759-67
2188735
J Clin Oncol. 2007 Oct 10;25(29):4557-61
17876013
J Clin Oncol. 2006 Oct 20;24(30):4914-21
17050875
J Clin Oncol. 2007 May 1;25(13):1658-64
17470858
J Clin Oncol. 2005 Mar 20;23(9):1803-10
15677699
Cancer Res. 1989 Sep 1;49(17):4682-9
2547513
J Clin Oncol. 2007 Aug 20;25(24):3644-8
17704414